Effective and
easy screening
Cologuard® finds colon cancer even in early stages when it is more treatable1,2
Cologuard sensitivity, per stage of cancer: I: 90% (n=29); II: 100% (n=21); III: 90% (n=10); IV: 75% (n=4).1
Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. False positives and false negatives may occur. In this clinical study, 13% of people without cancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative).1,3
Cologuard detects altered DNA and blood in your stool.
-
How does stool DNA technology work?
- Every day, your colon sheds cells that line the inside of the colon. As part of this process, altered cells will shed into the colon along with normal cells
- When you have a bowel movement, cells are collected by stool as it passes through your colon
- Cologuard uses advanced stool DNA technology to detect the DNA and blood cells released from altered cells, and can detect both precancer and cancer, if present
- Unlike other noninvasive colorectal cancer screening tests, Cologuard can detect both precancer and cancer
-
How often to screen with CologuardThe American Cancer Society recommends a screening interval every 3 years with Cologuard following a negative result.4 Cologuard performance in repeat testing has not been evaluated.
Cologuard is convenient
Cologuard is a noninvasive screening option you can use at home
- No special prep
- No need for time off
- No changes to your diet or medication
- Delivered to your doorstep
- Collect your sample in the privacy of your own home
Your Cologuard collection kit comes with simple instructions. And if you have any questions, you can call Customer Care 24/7 at 1-844-870-8870.
Choose your desired language for the video below to see how easy Cologuard can be to use
- English (US)
- English (US)
- العربية (Arabic)
- 简体中文 (Simplified Chinese)
- Français (French)
- 한국어 (Korean)
- Русский (Russian)
- Español (Spanish)
- Tagalog/Filipino
- Tiếng Việt (Vietnamese)
Who is Cologuard for?
If you are 45 and older and at average risk for colon cancer, Cologuard may be right for you. Cologuard is not for everyone. It is not a replacement for diagnostic or surveillance colonoscopy in high risk individuals. Ask a healthcare provider if Cologuard is right for you.
Cologuard may not be right for you if:
- You have a personal history of colon cancer, adenomas, or other related cancers
- You have a family history of colon cancer (one or more first-degree relatives diagnosed with colon or rectal cancer before the age of 60, or two or more first degree relatives diagnosed with colon or rectal cancer of any age)
- You have had a positive result from another screening method in the last six months
- You have been diagnosed with a condition that places you at high risk for colon cancer. These include but are not limited to: inflammatory bowel disease, chronic ulcerative colitis, Crohn's disease, familial adenomatous polyposis
- You have been diagnosed with a relevant cancer syndrome passed on from your family, such as hereditary nonpolyposis colorectal cancer syndrome, Peutz-Jeghers syndrome, MYH-associated polyposis, Gardner’s syndrome, Turcot’s (or Crail’s) syndrome, Cowden’s syndrome, juvenile polyposis, Cronkhite-Canada syndrome, neurofibromatosis, or familial hyperplastic polyposis
Results should be interpreted with caution for individuals over age 75, as the rate of false positives increases with age
References
1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297. 2. National Cancer Institute. Cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed January 8, 2020. 3. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci. 2015;60(3):623-633. 4. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guidelines update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281.